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transgenic HSC can engraft and evolve significant numbers of 
antigen specific T-cclls, which may in the future be utilized for 
targeted antigen specific GVL. 
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RESIDUAL HOST CHIMERISM AND PATTERN OF ANTIGEN EXPRES- 
SION INFLUENCE THE FATE OF ADOPTIVELY TRANSFERRED ALLO- 
GENIC T CELLS 
Dzlra/eovic, N.; F:/chs, E.J.; Lz:zJdk, L. The Si,lm 7 RTm::zel Comp're- 
he~zsive Cavce'r CeJl~e:" at ffoh:zs Hopleilzs, B,zlti1~lo:'e, MD. 
Donor lymphocyte infusions (DLI) and allogeneic T cells spe- 
cific for defined lninor histocompatibility antigen (±HAg) are 
increasingly used in the treatment of relapsed malignancies after 
allogeneic BMT. However, the fate and function of adoptively 
transferred T cells are poorly understood. To evaluate the role of 
host chimerism, complete and mixed chimeras were constructed 
by transplanting DBA/2 mice (H-2 d) with bone marrow (BM) 
from MHC-mismatched C56BL/6 (H-2 t') donors after myeloabla- 
tive and non-myeloablative conditioning, respectively. Three 
weeks later, both sets of chimeras received CFSE-labeled B6.SJL 
T ceils, which uniquely express the CD45.1 allele. On day 6 and 
10 after DLI administration, 86% and 93% of CD45.I + T ceils in 
mixed chimeras, respectively, and 41% and 63% of CD45.1 + T 
cells in full donor chimeras, respectively, underwent more than 7 
divisions. Serial monitoring of CD45.1 + T cells in full donor 
chimeras revealed that 28% of these cells remain undivided for 
more than 20 days. To define the effect of targeted antigen tissue 
expression pattern on the fate of allogeneic antigen-specific T 
cells, we used transgenic mice with wide (HA104) or pancreas- 
restricted (Ins-HA) expression of hemaglutinin (HA). TCR trans- 
genic Clone 4 (CL4) mice, which contain H-2K ~1 restricted CD8 + 
T cells specific for HA peptide were used as a source of antigen- 
specific T ceils. HA104 or Ins-HA mice on BALB/c background 
underwent BMT from MHC-compatible B10.D2 donors, fol- 
lowed by DLI from TCR transgenic B10.D2-CL4 mice three 
weeks later. Differential expression of the Thy 1.1 ÷ antigen on 
transgenic T cells was used for in vivo monitoring of their fate. 
Adoptively transferred TCR-specific transgenic CD8 ÷ T-cells 
engrafted, expanded, and then sharply declined and became unde- 
tectable in the mice with wide distribution of targeted HA anti- 
gen. In contrast, transgenic T ceils expanded but remained 
detectable for at least 30 days in the animals with pancreas- 
restricted HA expression without causing diabetes. However, co- 
administration of vaccinia virus expressing HA together with 
transgenic T cells resulted in diabetes. In conclusion, residual host 
chimerism, targeted antigens pattern of expression and antigen 
specific vaccinations have a potential to influence the late of adop- 
tively transferred allogeneic T-cells. 
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DONOR PRETREATMENT WITH G-CSF PREVENTS CHRONIC 
GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL 
TRANSPLANTATION 
z!/lacDol~alcl, I~P.I ; Rowe, V.1; Filippich, C J; CloustoJz, A.D.2; Fe:/'alrl, 
ff.L.S; Hill, G.R3 1. The Quee*zslmzd bzstitzlte of Medical Research, 
B:'isbmze, QLD, Azlst,-alia; 2. UMve'rsity of Qaee*Tslalzd, Bvisbmze, 
OLD, Az:st/:alia; 3. UMversit~, of Michigal~, Amz AT"l, or, ~/II. 
The incidence of extensive chronic GVHD (cGVHD) after 
allogeneic stem cell transplantation with G-CSF mobilised 
peripheral blood stem cell (PBSC) products is increased com- 
pared to that after bone *narrow transplantation a d necessitates 
prolonged, expensive and poorly effective immunosuppressive 
therapy. G-CSF is known to alter T cell function and PBSC 
products contain i0-20 times the number of T cells relative to 
bone marrow grafts, both of which may increase cGVHD. We 
have studied the effects of G-CSF and T cell dose on cGVHD in 
two well-described models manifested by either immune complex 
glomerulonephritis (DBA/2-+B6D2F1) or sclerodermatous 
hepatic and cutaneous fibrosis (Bl0.D2-+Balb/c). The former 
model induces GVHD to major and minor HA and the latter to 
minor HA only. Donor mice were treated with G-CSF (2ug/day) 
or diluent for 6 days and recipient mice were transplanted with 
unseparated donor splenocytes that contained equal numbers of 
T cells. In the immune complex model, 80% of SCT recipients 
that received grafts from control treated onors develop nephrot 
ic syndrome compared to 25% in the recipients of G-CSF treat- 
ed grafts (P<0.01) and mortality was decreased from 45 % to I5 % 
(P<0.05). Donor T cell engraftment and B cell activation (class II 
expression) were equivalent in both groups. The reduction in 
cGVHD following donor G-CSF pretreatment occurred in the 
setting of donor Th2 differentiation manifested by reduced inter- 
feron- 7 and increased IL 4 production with a concomitant 100- 
fold increase in the ratio of IgGl:IgG2c~ auto-antibody titres 
(P<0.05). In the scleroderma model, the effect of a 5-fold escalat- 
ed donor G-CSF T cell dose (G-CSF-high T) was compared to 
the low T cell dose (G-CSF-Iow T and control-low T), to mirror 
the effect of the high T cell doses transferred uring clinical 
peripheral blood stem cell transplantation. Hepatic and cuta- 
neous selni-qnantitative histopathology demonstrate hat sclero- 
dermatous cGVHD, characterised by epidermal thickening, 
fibrosis and procollagen deposition, is associated with high T cell 
doses but not G-CSF and Th2 differentiation per se (see table; 
*P<0.05, **P<0.01 v control). Thus, the limitation of T cell doses 
transferred uring PBSCT should reduce chronic GVHD con> 
pared to BMT, whilst maintaining the b neficial effects on graft 
quality. 
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DELAYED INFUSION OF DONOR CD4+25 + T CELLS CONTROLS 
GRAFT-VERSUS-HOST DISEASE WHILE ALLOWING AN EFFECTIVE 
GRAFT-VERSUS-LEUKEMIA RESPONSE 
Jom, s, S.C. ~; Mm'p,by, G. 2,Ko,r,,gold, R.1 . Thomas Jefferso~z Uzziversi- 
U, Kimmel Grocer blstitzLte, Philadelphia, PA; 2. ffeff'ersml Medical 
College, Dept of A*~atoJT~v, Pathology reed Cell Biolog3,, Philadelphia, PA. 
Following allogeneic hematopoietic cell transplantation (HCT), 
the high inverse correlation between graft-versus-host disease 
(GVIID) and leukemic relapse requires that calculated measures 
be taken to reduce GVHD pathology while retaining the graft- 
versus-leukemia effect (GVL). We sought o determine whether 
donor CD4+CD25 + regulatory T cells could control ongoing 
GVHD, effectively providing a window of time whereby the 
GVIt response is permitted to begin in favor of the elimination of 
residual leukemia ceils, before being brought under regulation to 
prevent he full development of lethal GVHD. Prevention of 
lethal GVHD by infusion of donor CD4+CD25 ÷ "F ceils early 
post-HCT (day 2) could be achieved across an MHC barrier in 
the haploidentical C3H into (B6xC3H)F1 model. However, in 
vitro pre-sensitization f donor CD4+CD25 ÷ T cells to recipient 
type alloantigen with high dose IL 2 was required for successful 
regulation. In contrast, in the minor histocompatabiIity antigen 
(miHA)-disparate, CDS-mediated B I0.BR into CBA GVHD 
model, lethal disease could be completely prevented by a single 
injection of freshly isolated donor CD4+CD25 + T cells, given as 
late as 10 days post-HCT. Of importance, this later regulato W 
effect required a CD4~CD25 + to effector CD8 ratio of only 1:3, 
indicating a strong potential for the delayed infusion of 
CD4+CD25 + T cells to control GVHD across miHA barriers. 
Furthermore, this regulation did not prevent complete and 
durable donor engraftment of the hematopoetic compartment. Of 
most significance, the day 10 infusion of donor CD4+CD25 + T 
cells into CBA HCT recipients that had been challenged with the 
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MM.CBA myeloid leukemia cell line did not block an effective 
GVL response, despite reducing lethal GVHD. These results 
demonstrate hat donor CD4+CD25 + T ceils infused early post- 
transplant can control the full development of GVItD without 
sacrificing asufficient GVL effect. 
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CD25 EXPRESSION DISTINGUISHES FUNCTIONALLY DISTINCT 
ALLOREACTIVE CD4+CDI34+ T CELL SUBSETS IN ACUTE GVHD 
Mazia'r.~, R.T.; Zhm~g, X.; Streete*', P.R. Medicine, OHSU, Port- 
land, OR. 
CD134 fOX40) is expressed on activated CD4+ donor T cells in 
antinals with aGVHD. Using a P--> FI rat BMT model of 
aGVHD, activated CD4+134+ T cells are shown to have a central 
role. These cells were evaluated, in vivo, using adoptive transfer. 
GVHD-associated donor CD4+134+ T cells were isolated from 
animals on D10, and the isolated cells were transferred to irradiat- 
ed (600R) F1 recipients with normal donor CD4-depleted CD8+ 
lymph node cells. This cell combination yielded lethal aGVHD in 
transplant recipients, while irradiated (600R) F1 control animals 
receiving either population alone failed to develop disease. Thus, 
aGVHD-associated CD4+134+ cells, as the only source of donor- 
derived CD4+ T cells, promote disease after adoptive transfer. 
However, in vitro challenge of the the aGVHD-associated 
CD4+134+ T cells with either host alloantigen or ConA provided 
only minimal proliferation. This T cell population was able to be 
stratified into CD25- and CD25+ subsets. CD4+134+25- T cells 
were selectively found in organized lymphoid tissues while 
CD4+134+25+ T cells were located in both organized lymphoid 
tissues and inflamed extralymphoid tissues. Although both 
CD4+134+ T cell subsets were observed throughout the disease 
course (D4 -->end stage), the CD4+134+25+ T subset predomi- 
nated on day 4. On D10, CD4+134+25- T cells proliferated to 
both ConA and allogeneic host leukocytes, while CD4+ 134+25 + T 
cells exhibited an anergic profile, with minimal response to either 
stimulus. Short-term culture of the CD4+134+25+ T cells to IL-2 
overcame T cell anergy, and cells recovered were alloresponsive. 
Thus, both CD4+ 134+ T cell subsets are comprised of alloreactive 
cells. When the anergic CD4+134+25+ T cells were added to 
responsive CD4+134+25- T cells, the CD4+134+25- cells no 
longer responded to antigen, indicating that CD4+134+25+ T 
cells inhibited the CD4+134+25- cell subset. The distinct issue 
localization, temporal induction and functional properties of these 
CD4+134+25- and CD4+134+25+ alloreactive T cell subsets ug- 
gest an unanticipated degree of complexity in the CD4+ T cell 
compartment in aGVHD. Clarification of the physiologic roles of 
the CD4+CD134+ subpopulations will provide insights into the 
temporal evolution of aGVHD. 
91 
T-CELL APOPTOSIS FOLLOWING NON-MYELOABLATIVE HEMATOPOI- 
ETIC CELL TRANSPLANTATION (HCT) 
Bhiis,~a~, FU; Si~lgleton, K.LS; LiTl, M.e; TabelliM, L.I; Fra~Tgoul, 
H.S; Damodaran, A.I; Hansen, ff.A. I i. Fred HlttchinsoJ~ Cai~cer 
Research Cellter, Seattle, WA; 2. National Taiwc.m UT~iversity, 
Taipei, TaiwaT~; 3. Vanderbih Unive~'sit~ Medical Ce~ter, 
Nashville, TN. 
We have previously demonstrated that PBMC from patients 
with aGVHD have high spontaneous'apoptosis following mye- 
loablative HCT. Short-term culture in the presence of dexam- 
ethasone or anti-CD3 monoclonfll antibody (Hum291) induces 
further apoptosis. We recently reported that monitoring sponta- 
neous; dexamethasone and anti-CD3 induced apoptosis may be 
useful for predicting steroid treatment outcome of GVHD in 
myeloablative HCT. We classified the outcome of steroid therapy 
into: (i)CR:complete response (no recurrence following steroid 
withdrawal) (ii)PR:partial/intermediate response(limited cGVHD, 
successfully withdrawn from immunosuppression) a d (iii) steroid 
dependent/refractory(SD/R): refractory GVHD or extensive 
GVHD requiring prolonged steroid/salvage therapy. Steroid 
dependent/refractory GVHD patients were very sensitive to anti- 
CD3 induced apoptosis after 4-weeks of steroid therapy. We now 
report our results in 25 patients undergoing non-myeloablative 
transplants. PBMC were obtained between day18-35 post-trans- 
plant and cultured for 24hours in medium and with Hum291 
(0.Sgg/ml). Apoptosis was measured by staining with 7AAD. In 
matched sibling donor transplants spontaneous apoptosis at day 
19-25 was 19.8+/-7.6% in 6 patients with aGVHD and 7.5+/- 
3.4% in 4 patients without any aGVHD(p<0.05) developing with- 
in 4 weeks of the assay. Spontaneous apoptosis was higher in URD 
transplants: 40.2+/-25.4% in 5 patients without aGVHD and 
I4.8+/-11.4% in 5 patients with aGVHD. GVHD requiring 
steroid therapy developed in 20 patients (10/14MSD, 10/11URD) 
between day 6-83 post-transplant (median 37.5 days). Assays were 
repeated after 4 weeks of steroid therapy. There was preferential 
anti-CD3 induced apoptosis in the SD/SR group(see table below). 
The pattern of apoptosis here is different from myeloablative 
transplantation, with an unexplained high spontaneous apoptosis 
in URD transplants without aGVHD. Preferential anti-CD3 
fuduced apoptosis occurs in non-myeloablative transplant patients 
who subsequently develop SD/SR GVHD. The correlation how- 
ever is not as strong, possibly due to other confounding factors 
including changing immune suppression i the non-myeloablative 
setting. 
Response Spontaneous Anti~CD3 p-value 
CR(n=4) 20.5+/7.9 23.4+/-8.1 NS 
PR(n=4) 11.7+/ 11.0 13.6+/-12.9 NS 
SD/SR(n=I2) 9.98+/-9.94 28.99+/9.9 ] <0.05 
I 
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THE LEUKEMIA-ASSOCIATED ANTIGEN PRI IS DERIVED FROM BOTH 
PROTEINASE 3 AND NEUTROPHIL ELASTASE PROTEINS 
OJ~o, Y.; St. ffohJ~, L.; Lu, S.; k~gl~g, C.; Mollch'em, ft. Blood & 
Marrow TraTz~Flantatio~, M. D. AJldersoTl Cancer Centre1", Hous- 
toTz, TX. 
PRI is an HLA-A2-restricted peptide leukemia-associated 
antigen that is contained within proteinase 3 (P3). We have 
shown that killing of leukemia cells by PRl-specific CTL corre- 
lates with P3 overexpression. However, the PR1 sequence is 
also contained within neutrophil elastase (NE), which is also 
aberrantly expressed in leukemia cells. To determine whether 
PR1 is processed and presented ffmn either protein, we used 
P3- and NE-transfected B cells as target cells in a proliferation 
assay with PRl-specific T cells. Full-length P3 and NE cDNA 
was cloned from the promyclocytic HL-60 cell line based on 
published sequences. The sequences were subcloned into an 
EGFP-containing vector (pCMS-EGFP) with a CMV promoter 
to drive constitutive xpression. The B cell line, HMy-CIR, 
previously stably transfected with the HLA-A*0201 gone, was 
transfected with P3-pCMS-EGFP and NE-pCMS-EGFP by 
electroporation for 24 hours. GFP expressing cells (P3- 
HMy.CIR-A2 and NE-HMy.CIR-A2, respectively) were select- 
ed by FACSorting and high transfection levels were confirmed 
by fluorescence microscopy. Quantitative real time PCR 
showed mRNA transcripts from one of two selected P3-trans- 
fected clones were only 2.6-fold less than HL-60 cells (p = 
0.07), and only 1.5-fold less in a second clone (p = 0.3). By con- 
trast, NE transcript numbers from a transfected clone were 7- 
fold.less than in HL-60 cells. Western blotting confirmed pro- 
tein expression in the NE-HMy.CIR-A2-transfected cells, 
although expression was similarly less than in HL-60 cells. 
PRl-specif ic CTL lines elicited from two healthy donors 
showed stimulation i dices (SI) of 1.3 and 2.4 When coincubated 
with P3-HMy.CIR-A2 target cells during BrDU incorporation, 
confirming that PR1-CTL recognize PR1 peptide processed 
and presented from P3. Interestingly, PR1-CTL also recog- 
nized NE-transfected cells, with SI of 1.5 and 2.1. No recogni- 
tion of non-transfectants or parent HMy.CIR (A2-) was 
observed. These results demonstrate that, in addition to P3, 
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